To evaluate the maternal and neonatal complications after frozen-thawed blastocyst transfer cycles utilizing different endometrial preparation regimens. This is a retrospective cohort study and a secondary analysis of a multicenter, randomized, controlled trial comparing live birth rate after fresh vs. frozen single blastocyst transfer (Frefro-blastocyst). Reproductive medicine centers. A total of 800 women with regular menstrual cycles undergoing their first cycle of fertilization after frozen-thawed single blastocyst transfer. Endometrium preparation was performed with a natural cycle regimen or hormone replacement therapy (HRT) cycle regimen, at the discretion of local investigators. All pregnancies were followed up until delivery. Maternal and neonatal complications. 513 infertile patients who underwent natural cycles regimen and 287 who underwent HRT cycles regimen were analyzed. The incidences of maternal and neonatal complications were comparable between the natural cycle and HRT cycle regimen. Regarding the risk of gestational diabetes, gestational hypertension, pre-eclampsia, preterm delivery, small for gestational age and large for gestational age, the HRT cycle was still not a significant risk factor after adjusting for potential confounders. The natural cycle regimen yielded an insignificant higher total live birth rate [59.45 vs. 50.17%, = 0.001, adjusted odds ratio (AOR) 1.366, 95% confidence interval (CI) 0.975-1.913], clinical pregnancy rate (68.23 vs. 58.89%, = 0.008, AOR 1.406, 95% CI 0.992-1.991) and ongoing pregnancy rate (62.18 vs. 52.61%, = 0.008, AOR 1.387, 95% CI 0.988-1.948) than did the HRT cycle regimen. However, compared to natural cycles, HRT cycles were associated with a significantly higher risk of biochemical miscarriage (6.86 vs. 18.18%, < 0.001, AOR 0.328, 95% CI, 0.176-0.611). The incidence of maternal and neonatal complications in natural cycle and HRT cycle regimens after frozen single blastocyst transfer were comparable. Frozen-thawed single blastocyst transfer in a natural cycle was associated with lower biomedical miscarriage than the use of the HRT cycle. Frefro-blastocyst was registered at Chinese Clinical Trial Registry, ChiCTR-IOR-14005405.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483478PMC
http://dx.doi.org/10.3389/fmed.2020.00338DOI Listing

Publication Analysis

Top Keywords

cycle regimen
24
blastocyst transfer
24
hrt cycle
24
maternal neonatal
20
neonatal complications
20
single blastocyst
20
natural cycle
20
cycle
13
frozen single
12
natural
8

Similar Publications

Infertility has emerged as a significant global health concern. Assisted reproductive technology (ART) assists numerous infertile couples in conceiving, yet some experience repeated, unsuccessful cycles. This study aims to identify the pivotal clinical factors influencing the success of fresh embryo transfer of in vitro fertilization (IVF).

View Article and Find Full Text PDF

Primary Renal Lymphoma: A Single-Center Study of 14 Cases.

Clin Genitourin Cancer

January 2025

Department of Pathology, The First Medical Centre, Chinese PLA General Hospital, Beijing, China. Electronic address:

Objective: To investigate the clinical characteristics, pathology, imaging features, and prognosis of primary renal lymphoma (PRL), a rare malignancy.

Patients And Method: We conducted a retrospective review of 14 PRL cases diagnosed between January 2009 and January 2022, with follow-up data collected from medical records.

Results: The study included 14 patients (7 males, 7 females), with a mean age of 60.

View Article and Find Full Text PDF

The potential benefits of pyrotinib for patients with trastuzumab-insensitive, HER2-positive early-stage breast cancer remain unclear. This prospective, multicentre, response-adapted study evaluated the efficacy and safety of adding pyrotinib to the neoadjuvant treatment of HER2-positive breast cancer patients with a poor response to initial docetaxel plus carboplatin and trastuzumab (TCbH). Early response was assessed using magnetic resonance imaging (MRI) after two cycles of treatment.

View Article and Find Full Text PDF

Objective: Standard treatment of metastatic colorectal cancer includes oxaliplatin and 5-fluorouracil in continuous infusion. Although FOLFOX-6 is the reference combination, it is aggressive and has high toxicity. Variants such as the TTD regimen, which does not include folinic acid or 5-fluorouracil bolus, are used.

View Article and Find Full Text PDF

A Decade of Oocyte Cryopreservation: New Horizons in Patients Accessing Care.

J Womens Health (Larchmt)

January 2025

Reproductive Medicine Associates of NY, New York, NY, USA.

Utilization of fertility preservation treatments has increased since the American Society for Reproductive Medicine lifted the "experimental" label for oocyte cryopreservation in 2012. This study characterizes changes in insurance coverage, clinical outcomes, and live birth probabilities over a span of a decade (2012-2022) in patients who underwent planned oocyte cryopreservation. Retrospective analysis of planned oocyte cryopreservation cycles using vitrification from 2012 to 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!